Who: GlaxoSmithKline/Immatics Biotechnologies
What: GSK and Immatics will collaborate on development of T-cell receptor (TCR) therapeutics for solid tumors against
GSK Partnership With Immatics Seeks TCR Therapeutics For Solid Tumors
Deal Snapshot: GSK obtains rights to two of Immatics’ TCR targets, following on the German firm’s similar deals in recent years with Celgene, Genmab and Amgen.
More from Deals
More from Business
• By
The sector is continuing to show resilience despite financial and market challenges.
• By
Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.
• By
The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.